Ardelyx (ARDX) said Wednesday that a new drug application for tenapanor for the treatment of hyperphosphatemia has received approval from China's Center for Drug Evaluation of the National Medical Products Administration.
Tenapanor received approval to control serum phosphorus levels in dialysis patients with chronic kidney disease with an inadequate response or who are intolerant to phosphorus binders, Ardelyx said.
The company said that following the approval, it will receive a $5 million milestone payment from its collaboration partner in China, Shanghai Fosun Pharmaceutical Industrial Development. Ardelyx said that under the terms of their license agreement, it is eligible to receive up to $100 million in additional developmental and commercialization milestones and tiered royalty payments on net sales of mid-teens to 20%.
The company said Shanghai Fosun Pharmaceutical has the exclusive rights to market and sell tenapanor in China, Hong Kong and Macau, with tenapanor to be marketed with the Chinese trade name Wan Ti Le.
Shares were 1.4% higher ahead of Wednesday's opening bell.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。